Extractables and leachables threaten drug safety. Advancements in AI, testing, and analytics target to manage these risks for better regulatory compliance.
MRR is changing pharma analysis by offering detailed structural information on complex mixtures, reducing separation time, and improving process efficiency.
AI and ML offer pharmaceutical firms data-driven insights for R&D but require overcoming challenges in data integration and quality aided by ACD-Labs solutions.
A new nickel complex allows researchers to create drugs faster by simplifying alkyl bond formation, cutting drug development costs and improving efficiency.
With M&A and partnerships on the rise,the radiopharmaceutical sector is booming, offering significant investment options as it continues to expand swiftly.
